1. Grün G, Fleckenstein A (1972) Die elektromechanische Entkoppelung der glatten Gefäßmuskulatur als Grundprinzip der Coronardilation durch 4-(2?-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridin-3, 5-dicarbonsäure-dimethylester (BAY a 1040, Nifedipine). Arzneim Forsch 22: 334?344
2. Murakami M, Murakami E, Takekoshi N, Tsuchiya M, Kin T, Onoe T, Takeuchi N, Funatsu T, Hara S, Ishise S, Mifune J, Maeda M (1972) Antihypertensive effect of 4(-2?-Nitrophenyl)-2, 6-Dimethyl-1, 4-Dihydropyridine-3, 5-Dicarbonic acid dimethylester (Nifedipine Bay-a 1040), a new coronary dilator. Jpn Heart J 13: 128?135
3. Aoki K, Yoshida T, Kato S, Tazumi K, Sato I, Takikawa K, Hotta K (1976) Hypotensive action and increased plasma renin activity by Ca2+ antagonist (nifedipine) in hypertensive patients. Jpn Heart J 17: 479?484
4. Aoki K, Kondo S, Mochizuki A, Yoshida T, Kato K, Takikawa K (1978) Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade. Am Heart J 96: 218?226
5. Aoki K, Kondo S, Mochizuki A, Sato K, Yoshida T, Kato S, Kato K (1979) Ca2+-antagonist therapy for hypertension in combination with beta-blockade: A new concept of essential hypertension. In: Yamori Y, Lovenberg W, Freis ED (eds) Prophylactic approach to hypertensive diseases. Raven Press, New York, pp 377?386